[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100421079":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":60,"collaborators":11,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":11,"eligibilityCriteria":69,"healthyVolunteers":66,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":11,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":32,"whyStopped":11,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Cedars-Sinai Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Whole-Body Magnetic Resonance Imaging","EXPERIMENTAL",null,[13],"Other: Whole-body Magnetic Resonance Imaging",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":11},"Whole-body Magnetic Resonance Imaging","Whole-body Magnetic Resonance Imaging at baseline, 1 month, and 12 months",[9],[20],{"name":21,"affiliation":5,"role":22},"Nicole Baca, MD","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Clinical Trial Recruitment Navigator","CONTACT","3104232133","GroupCancerTrialInformation@cshs.org",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Cedars Sinai Medical Center","RECRUITING","Los Angeles","California","90048","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-118.24368,34.05223,{"lat":42,"lon":41},[45,47,50,52,54,56,58],{"name":25,"role":26,"phone":46,"phoneExt":11,"email":28},"310-423-2133",{"name":48,"role":49,"phone":11,"phoneExt":11,"email":11},"Fataneh Majlessipour, MD","SUB_INVESTIGATOR",{"name":51,"role":49,"phone":11,"phoneExt":11,"email":11},"Pedro Sanchez, MD, MSCE",{"name":53,"role":49,"phone":11,"phoneExt":11,"email":11},"Edwin Posadas, MD",{"name":55,"role":49,"phone":11,"phoneExt":11,"email":11},"Debiao Li, PhD",{"name":57,"role":49,"phone":11,"phoneExt":11,"email":11},"Yibin Xie, PhD",{"name":59,"role":49,"phone":11,"phoneExt":11,"email":11},"Touseef Qureshi, PhD",{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Nicole Baca","Assistant Professor of Department of Pediatrics","100421079","identification-of-pre-malignant-lesions-in-pediatric-patients-with-neurofibromatosis-type-1-using-novel-magnetic-resonance-imaging-techniques-paired-with-artificial-intelligence-100421079",false,"NCT04763109","Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence","Inclusion Criteria:\n\n* Between the ages of 5 and \\\u003C18 years at the start of study. If subject will turn 18 during the study, they will be allowed to enroll.\n* Clinically or molecularly confirmed diagnosis of NF-1. Subjects with mosaic\u002Fsegmental NF-1 also qualify for the study.\n\nExclusion Criteria:\n\n* Requiring sedation for imaging.\n* Implants and\u002For Devices: Mechanical, magnetic or electrical activated implants; Ferromagnetic implants and foreign bodies\n* Claustrophobia, problems being in enclosed spaces, or inability to lie facing upwards.\n* Allergy to animal dander or animal-instigated asthma.","ALL","5 Years","17 Years",{"count":74,"type":75},15,"ESTIMATED","INTERVENTIONAL",[78],"NA","This is a single arm pilot trial of a novel whole-body Magnetic Resonance Imaging paired with artificial intelligence intervention, to evaluate feasibility defined as scan-rescan reliability, and to estimate the positive predictive value of changes in Magnetic Resonance Imaging scans from baseline to 12-month visit using an Artificial Intelligence algorithm, among 15 pediatric patients with neurofibromatosis type 1 at Cedars-Sinai Medical Center.",[81],"Neurofibromatosis Type 1",[83,81,84],"Pediatric","magnetic resonance imaging","2026-05-01",{"date":87,"type":88},"2026-05-07","ACTUAL",{"date":90,"type":88},"2022-07-08",{"date":92,"type":75},"2029-05",{"name":62,"class":6},1]